• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Ruzurgi (amifampridine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Ruzurgi (amifampridine)

  • Profile

Profile

Contact Information

Contact: Jacobus Pharmaceutical
Website: https://ruzurgi.com/

Currently Enrolling Trials

    Show More

    General Information

    Ruzurgi (amifampridine) is a potassium channel blocker.

    Ruzurgi is specifically indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.

    Ruzurgi is supplied as a tablet for oral administration. The recommended dose is as follows:

    Patients 6 to less than 17 years of age and weighing 45 kg or more:

    • Initial dose is 15 to 30 mg daily, in divided doses. Increase daily in 5 to 10 mg increments, divided in up to 5 doses daily
    • Maximum single dose is 30 mg; maximum daily dose is 100 mg

    Patients 6 to less than 17 years and weighing less than 45 kg:

    • Initial dose is 7.5 to 15 mg daily, in divided doses. Increase daily in 2.5 mg to 5 mg increments, divided in up to 5 doses daily
    • Maximum single dose is 15 mg; maximum daily dose is 50 mg.

    Mechanism of Action

    Ruzurgi (amifampridine) is a potassium channel blocker. The mechanism by which Ruzurgi exerts its therapeutic effects on LEMS patients is not fully understood.

    Side Effects

    Adverse effects associated with the use of Ruzurgi may include, but are not limited to, the following:

    • burning or prickling sensation (paresthesia)
    • abdominal pain
    • indigestion
    • dizziness
    • nausea
    • Seizures have been observed in patients without a history of seizures.

    Clinical Trial Results

    The FDA approval of Ruzurgi was based on a randomized, double-blind, placebo-controlled withdrawal study of 32 adult patients in which patients were taking Ruzurgi for at least three months prior to entering the study. The study compared patients continuing on Ruzurgi to patients switched to placebo. The primary measure of efficacy was the categorization of the degree of change (e.g., greater than 30% deterioration) in the Triple Timed Up and Go test (3TUG) upon withdrawal of active medication, when compared with the time-matched average of the 3TUG assessments at baseline. The 3TUG is a measure of the time it takes a person to rise from a chair, walk 3 meters, and return to the chair for 3 consecutive laps without pause. Higher 3TUG scores represent greater impairment. None of the patients randomized to continue on Ruzurgi experienced a greater than 30% deterioration in the final post-dose 3TUG test. In contrast, 72% of the patients in the placebo group did experience a greater than 30% deterioration in the final post-dose 3TUG test.

    Approval Date: 2019-05-01
    Company Name: Jacobus Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing